Supplementary Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

Table S1. shows progression Free Survival in individual subjects. Table S2. show exposures to epirubicinol in subjects who received infusion of NC-6300. Figure S1. shows total epirubicin concentrations (mean {plus minus} SD) at the end of infusion of 170 mg/m2 NC-6300 across cycles. Figure S2. shows mean Change in EORTC QLQ-C30 Score from Baseline.